Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

Direct Sales At Lower Prices?

 
• By Jung Won Shin
  
big opportunity
Trump’s Executive Orders May Positively Impact Biosimilar Industry (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Drug Pricing